View Older Stories View More Recent Stories

May 16, 2022 04:02PM Form 13F-HR Atlas Venture Life Scien For: Mar 31
May 16, 2022 03:54PM Form 13F-HR Atlas Venture Life Scien For: Dec 31
May 12, 2022 01:48PM Form 13F-NT Atlas Venture Fund VIII, For: Mar 31
May 12, 2022 01:46PM Form 13F-NT Atlas Venture Associates For: Mar 31
May 12, 2022 01:44PM Form 13F-NT Atlas Venture Associates For: Mar 31
May 12, 2022 01:38PM Form 13F-HR Atlas Venture Advisors, For: Mar 31
May 12, 2022 01:37PM Form 13F-HR Atlas Venture Associates For: Mar 31
May 5, 2022 04:06PM Form SC 13D/A Aerovate Therapeutics, Filed by: Atlas Venture Fund XII, L.P.
May 5, 2022 04:02PM Form SC 13D/A Magenta Therapeutics, Filed by: Atlas Venture Fund X, L.P.
Apr 26, 2022 07:00AM Vedere Bio II Appoints Accomplished Clinician and Researcher Anna-Maria Demetriades as Chief Medical Officer
Apr 25, 2022 08:04AM Perspective Group Announcing the Formation of an Advisory Board
Apr 19, 2022 08:00AM Sionna Therapeutics Launches with $111 Million Series B Financing to Advance Pipeline of Novel Small Molecules with the Potential to Fully Restore CFTR Function in Cystic Fibrosis
Apr 14, 2022 06:30AM Be Bio Closes $130 Million Financing to Pioneer Engineered B Cells, a New Class of Cellular Medicines
Apr 12, 2022 07:00AM Vedere Bio II Announces Appointment of Industry Veteran Gina Consylman as Chief Financial Officer
Apr 11, 2022 04:01AM Highview Power Names Rupert Pearce Chief Executive Officer
Apr 6, 2022 09:00AM  TRIANA Biomedicines Launches With $110M to Unlock the Full Potential of Molecular Glues
Apr 4, 2022 05:13PM Form 4 Aerovate Therapeutics, For: Apr 01 Filed by: Atlas Venture Fund XII, L.P.
Apr 4, 2022 08:00AM Scorpion Therapeutics Appoints Saurabh Saha, M.D., Ph.D. to its Board of Directors
Mar 3, 2022 03:09PM Form D Atlas Venture Fund XIII,
Mar 3, 2022 07:00AM Atlas Venture Announces $450 Million Fund XIII
Feb 16, 2022 06:00AM Third Harmonic Bio Launches to Advance the Next Wave of Medicine for Allergy and Inflammation
Feb 14, 2022 06:18AM Form SC 13G/A F-star Therapeutics, Filed by: Atlas Venture Opportunity Fund I, L.P.
Feb 11, 2022 05:40PM Form SC 13G/A Akero Therapeutics, Inc. Filed by: Atlas Venture Fund XI, L.P.
Feb 11, 2022 05:28PM Form SC 13G/A Kymera Therapeutics, Filed by: Atlas Venture Fund X, L.P.
Feb 11, 2022 05:23PM Form SC 13G Day One Biopharmaceutica Filed by: Atlas Venture Fund XI, L.P.
Feb 11, 2022 05:20PM Form SC 13D Ikena Oncology, Inc. Filed by: Atlas Venture Fund X, L.P.
Feb 11, 2022 05:18PM Form SC 13G/A Dyne Therapeutics, Inc. Filed by: Atlas Venture Fund XI, L.P.
Feb 11, 2022 05:14PM Form SC 13G/A Generation Bio Co. Filed by: Atlas Venture Fund X, L.P.
Feb 10, 2022 07:00AM Arkuda Therapeutics Raises $64 Million Series B Financing to Advance Pipeline of Programs Targeting Lysosomal Biology to Treat Neurodegenerative Diseases
Feb 8, 2022 07:00AM Vedere Bio II Appoints Martina Schinke, Ph.D., as Vice President, Program Leader
Feb 7, 2022 03:39PM Form SC 13G INTEGRAL AD SCIENCE HOLD Filed by: Atlas Venture Fund VIII, L.P.
Jan 27, 2022 10:53AM Form 13F-HR Atlas Venture Advisors, For: Dec 31
Jan 27, 2022 06:08AM Form 13F-NT Atlas Venture Fund VIII, For: Dec 31
Jan 27, 2022 06:05AM Form 13F-NT Atlas Venture Associates For: Dec 31
Jan 27, 2022 06:05AM Form 13F-NT Atlas Venture Associates For: Dec 31
Jan 27, 2022 06:04AM Form 13F-HR Atlas Venture Associates For: Dec 31
Jan 25, 2022 11:33AM Form SC 13G/A Cogent Biosciences, Inc. Filed by: Atlas Venture Fund IX, L.P.
Jan 25, 2022 11:31AM Form SC 13G/A Surface Oncology, Inc. Filed by: Atlas Venture Fund IX, L.P.
Jan 25, 2022 11:29AM Form SC 13G/A Spero Therapeutics, Inc. Filed by: Atlas Venture Fund IX, L.P.
Jan 21, 2022 04:40PM Form SC 13D Vigil Neuroscience, Inc. Filed by: Atlas Venture Fund XII, L.P.
Jan 11, 2022 09:16PM Form 4 Vigil Neuroscience, Inc. For: Jan 11 Filed by: Atlas Venture Opportunity Fund I, L.P.
Jan 6, 2022 08:30PM Form 3 Vigil Neuroscience, Inc. For: Jan 06 Filed by: Atlas Venture Opportunity Fund I, L.P.
Jan 5, 2022 07:30AM Korro Bio Completes $116M Series B Financing to Expand the Frontier of Genetic Medicine Through Its Pipeline of RNA Editing Programs
Dec 14, 2021 08:28PM Form 4 Ikena Oncology, Inc. For: Mar 30 Filed by: Atlas Venture Fund XI, L.P.
Dec 9, 2021 07:00AM K36 Therapeutics Launches with $30 Million Series A Financing from F-Prime Capital and Atlas Venture with Eight Roads Ventures
Dec 8, 2021 07:03AM Ikena Oncology Inc. (IKNA) Appoints Michelle Zhang as Chief Scientific Officer
Dec 8, 2021 07:00AM Ikena Appoints Michelle Zhang, Ph.D., Industry and Company Veteran, as Chief Scientific Officer
Dec 8, 2021 07:00AM Ikena Appoints Michelle Zhang, Ph.D., Industry and Company Veteran, as Chief Scientific Officer
Dec 1, 2021 06:30AM Curie Therapeutics Raises $75 Million Financing to Further its Mission of Transforming Cancer Care with Precision Radiopharmaceuticals
Nov 29, 2021 05:34PM Form 4 Day One Biopharmaceutica For: Nov 24 Filed by: Atlas Venture Fund XI, L.P.
View More Recent Stories View Older Stories